Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 240-242

  Tano, E ^a   Cars, O ^a   Löwdin, Elisabet ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HEp 2 cells; Pharmacokinetics; Quinolones

Indexed keywords

ERYTHROMYCIN; GENTAMICIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ACCURACY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; CELL CULTURE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PREDICTION; SIMULATION; BIOLOGICAL MODEL; CELL LINE; COMPARATIVE STUDY; DRUG EFFECT; KINETICS; MICROBIOLOGICAL EXAMINATION;

AZA COMPOUNDS; CELL LINE; ERYTHROMYCIN; HUMANS; KINETICS; LEGIONELLA PNEUMOPHILA; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; QUINOLINES;

EID: 24044555576     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki159     Document Type: Article

References (10)

1. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin erythromycin and rifampicin used singly and in combination against Legionella pneumophila. [i#Antimicrob Agents Chemother#1i] 1995; [b#39#1b]: 1661-6.
2. Jonas D, Engels I, Daschner FD [i#et al.#1i] The effect of azithromycin on intracellular [i#Legionella pneumophila#1i] in the mono 6 cell line at serum concentrations attainable [i#in vivo. J Antimicrob Chemother#1i] 2000; [b#46#1b]: 385-90.
3. Hultén K, Rigio R, Gustafsson I [i#et al.#1i] New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. [i#Antimicrob Agents Chemother#1i] 1996; [b#40#1b]: 2727-31.
4. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. [i#J Antimicrob Chemother#1i] 1999; [b#43#1b]: 83-90.
5. Barré J, Tillement JP. Protein binding of macrolide antibiotics. In: Bryskier AJ, Butzler JP, Neu HC, [i#et al.#1i], eds, [i#Macrolides Chemistry, Pharmacology and Clinical Uses#1i]. Paris: Arnette Blackwell, 1993; 437-40.
6. Louise J, Oldham J, Frank GR. Adhesion, penetration and intracellular replication of [i#Legionella pneumophila#1i]: An [i#in vitro#1i] model of pathogenesis. [i#J Gen Microbiol#1i] 1985; [b#131#1b]: 697-706.
7. Baltch AL, Smith RP, Franke MA [i#et al.#1i] Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against [i#Legionella pneumophila. Antimicrob Agents Chemother#1i] 1998; [b#42#1b]: 3153-6.
8. Ruckdeschel G, Dalhoff A. The in-vitro activity of moxifloxacin against [i#Legionella#1i] species and the effects of medium on susceptibility test results. [i#J Antimicrob Chemother#1i] 1999; [b#47#1b] (Suppl B): 25-9.
9. Dubois J, St-Pierre C. In vitro susceptibility study of BMS-284756 against [i#Legionella#1i] species. [i#Diagn Microbiol Infect Dis#1i] 2001; [b#41#1b]: 79-82.
10. Jonas D, Engels I, Friedhoff C [i#et al.#1i] Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular [i#Legionella pneumophila. J Antimicrob Chemother#1i] 2001; [b#47#1b]: 147-52.